On June 12th, Gelonhui announced that Zejin Pharmaceutical (688266.SH) has achieved the primary efficacy endpoint of the Phase III clinical trial (plan number: ZGJAK018) for the treatment of severe alopecia areata with the newly developed Class 1 drug Gicasitini hydrochloride tablets (formerly known as Jacktin hydrochloride tablets). It reached statistical significance (p < 0.0001) in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial on the efficacy and safety of Gicasitini hydrochloride tablets in the treatment of severe alopecia areata patients. The company will accelerate the launch process of Gicasitini hydrochloride tablets for the treatment of severe alopecia areata.
泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗重症斑秃III期临床试验达到主要疗效终点
Zejiang Pharmaceutical (688266.SH): The Phase III clinical trial of JAK inhibitor GDC-0853 hydrochloride tablets for the treatment of severe alopecia areata has reached the primary endpoint of therapeutic effect.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.